

# Correction of sub-clinical prolongation of COAGulation tests and/or low platelets before TRACHeotomy: randomised controlled trial

<b>Submission date</b> 19/07/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 19/07/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 02/08/2012	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr D.P Veelo

**Contact details**  
Academic Medical Center  
Department of Intensive Care  
Meibergdreef 5  
Amsterdam  
Netherlands  
1105 AZ  
+31 (0)20 5666345  
d.p.veelo@amc.uva.nl

## Additional identifiers

**Protocol serial number**  
NTR694

## Study information

**Scientific Title**

**Acronym**

The COAG-TRACH study

**Study objectives**

Correction of sub-clinical prolongation of coagulation tests (i.e. partial thromboplastin time [PTT] between 14.7 - 20 seconds and platelets less than  $100 \times 10^9/l$ ) and transfusion of platelets in patients taking Ascal®, significantly decreases the incidence of clinically significant peri-procedural bleeding.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval received from the local medical ethics committee

**Study design**

Randomised, single blinded, active controlled, parallel group trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Blood coagulation disorders, percutaneous tracheotomy (PDT)

**Interventions**

In group 1, patients receive platelets and/or plasma before PDT until normal values are reached. In group 2, patients do not receive platelets and/or plasma.

**Intervention Type**

Procedure/Surgery

**Phase**

Not Specified

**Primary outcome(s)**

1. The volume of blood loss during PDT
2. The intensity of intra-tracheal bleeding
3. Time until no blood is visible in tracheal aspirates

**Key secondary outcome(s)**

The amount of blood products used during and after tracheotomy

**Completion date**

01/07/2009

# Eligibility

## Key inclusion criteria

1. Sub-clinical lengthening of coagulation
2. Tests and/or low platelets
3. Use of Ascal®
4. Planned percutaneous tracheotomy (PDT)
5. Aged greater than 18 years
6. Informed consent

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

## Sex

All

## Key exclusion criteria

1. Contraindications for percutaneous tracheotomy (PDT) (i.e. surgical tracheotomy is preferred)
2. Contraindications for transfusion of blood products
3. Contraindication for correction of coagulation disorders
4. PTT greater than 20 seconds
5. Use of clopidogrel

## Date of first enrolment

01/07/2006

## Date of final enrolment

01/07/2009

# Locations

## Countries of recruitment

Netherlands

## Study participating centre

Academic Medical Center

Amsterdam

Netherlands

1105 AZ

# Sponsor information

## Organisation

Academic Medical Centre (AMC) (The Netherlands) - Department of Intensive Care

## ROR

<https://ror.org/03t4gr691>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Academic Medical Centre (AMC) (The Netherlands) - Department of Intensive Care

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/04/2012		Yes	No